Deep Brain Stimulation (DBS) — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Deep brain stimulation (DBS) is a neurosurgical procedure in which thin insulated electrodes with four contact points are stereotactically implanted into specific deep brain nuclei — principally the subthalamic nucleus (STN) or globus pallidus interna (GPi) for movement disorders, and the anterior limb of the internal capsule or the nucleus accumbens for psychiatric conditions. The electrodes are connected by subcutaneous extension cables to a programmable implantable pulse generator (IPG) implanted under the skin of the chest wall, analogous to a cardiac pacemaker. The IPG delivers continuous high-frequency electrical pulses (typically 130–185 Hz, 60–90 microsecond pulse width, 1–5 volts) that modulate abnormal neural circuit activity. The exact mechanism by which DBS produces its therapeutic effect remains incompletely understood but involves depolarisation blockade, synaptic inhibition, and disruption of pathological oscillatory synchrony within basal ganglia-thalamocortical circuits. DBS is entirely reversible — the stimulation can be adjusted or turned off — distinguishing it from ablative procedures such as thalamotomy and pallidotomy. Neurosurgeons specialising in functional neurosurgery and neurologists specialising in movement disorders collaborate in DBS candidacy assessment, surgery, and long-term programming. Globally, over 200,000 patients live with implanted DBS systems.

In Parkinson's disease, DBS is indicated for patients who have documented motor fluctuations and dyskinesia not adequately controlled by optimal medical management, whose motor symptoms show a good response to levodopa (at least thirty percent improvement on the UPDRS motor scale in the on versus off medication states), and who have adequate cognition and absence of severe psychiatric comorbidity. A minimum disease duration of five years from diagnosis is generally required to ensure the diagnosis is established and alternative Parkinson-plus syndromes (MSA, PSP, CBD) are excluded. In essential tremor, DBS of the ventral intermediate nucleus (VIM) of the thalamus is indicated for medically refractory disabling limb tremor causing functional impairment — the most effective surgical treatment for tremor, with better results than STN DBS for tremor-predominant disease. Primary generalised and segmental dystonia — particularly DYT1 mutation-positive dystonia — responds well to GPi DBS with benefit emerging over three to twelve months. Obsessive-compulsive disorder (OCD) refractory to pharmacotherapy and psychotherapy is a licensed indication for DBS in the USA and Europe (HUD/CE mark). Investigation for DBS suitability requires multidisciplinary evaluation including movement disorder neurology, neuropsychology, neuropsychiatry, and neurosurgery.

DBS surgery is typically performed in two stages. In the first stage, the patient is admitted the day before for preparation. A stereotactic frame (Leksell or similar) is fixed to the skull under local anaesthesia, or a frameless stereotactic system using bone-implanted fiducial markers is used. High-resolution MRI and CT are fused to identify the STN or GPi target coordinates with sub-millimetre accuracy. In the operating theatre, the patient remains awake to allow intraoperative neurophysiology (microelectrode recording of single-unit activity and neuronal firing patterns to refine target localisation) and macrostimulation testing to confirm therapeutic effect and exclude side effects before permanent electrode placement. One or two burr holes are made in the skull under local anaesthesia. The DBS lead is advanced along the planned trajectory through brain tissue to the target and fixed at the skull. In the second stage — usually performed the same day under general anaesthesia or the following day — the IPG is implanted subcutaneously in the infraclavicular region or upper chest. Extension cables are tunnelled subcutaneously from the skull to the chest. The IPG is programmed approximately two to four weeks after surgery when postoperative swelling has settled, and parameters are refined at multiple programming sessions over three to six months.

Deep brain stimulation produces substantial and sustained motor improvements in appropriately selected patients. In Parkinson's disease, landmark randomised controlled trials (EARLYSTIM trial, Weaver et al. NEJM 2009, Williams et al. Lancet 2010) demonstrate that STN DBS reduces motor fluctuation time (off periods) by fifty to sixty percent, reduces dyskinesia by sixty to seventy percent, and allows significant reduction in dopaminergic medication dose — reducing drug-related side effects. Quality of life scores (PDQ-39) improve significantly at five years compared to best medical therapy. Essential tremor treated with VIM DBS achieves greater than seventy percent tremor reduction in eighty to ninety percent of patients, enabling patients to resume activities of daily living, handwriting, and self-care. GPi DBS for DYT1 dystonia achieves fifty to eighty percent improvement in the Burke-Fahn-Marsden Dystonia Rating Scale over six to twelve months. DBS for OCD (using anterior limb of internal capsule targets) achieves thirty to forty percent reduction in Y-BOCS scores in sixty percent of patients. Critically, DBS preserves all brain tissue and is reversible — it can be adjusted, reprogrammed, or turned off if side effects or inadequate efficacy develop.

Surgical risks of DBS include intracranial haemorrhage from electrode insertion, which occurs in one to two percent of surgeries and may cause stroke symptoms in approximately one percent of patients. Infection of the device components — electrode, extension, or IPG — occurs in two to five percent of cases and may require temporary or permanent device explantation. Lead migration or fracture requires surgical revision in approximately three to five percent of patients over the device lifetime. IPG malfunction may require replacement of the generator, which becomes necessary every three to twelve years depending on the model (primary cell versus rechargeable) and stimulation settings. Stimulation-induced side effects depend on the target: STN DBS may cause speech difficulties (dysarthria, hypophonia), cognitive slowing, impulsivity, or stimulation-related dyskinesia; VIM DBS for tremor may cause paraesthesia and rarely worsening balance; GPi DBS produces fewer cognitive side effects than STN DBS and is preferred in patients with mild cognitive impairment. Surgical risks from awake craniotomy include anxiety, hypertension, and rarely seizure. Device infection and lead migration are the most common late complications requiring reoperation.

After DBS electrode implantation and IPG placement, patients spend two to five days in hospital for wound monitoring and neurological observation. The scalp wound and chest incision heal over ten to fourteen days. Initial activation of the stimulator occurs at two to four weeks post-surgery when oedema around the electrode has resolved. The first programming session establishes stimulation parameters — electrode contact selection, frequency, pulse width, and amplitude — and Parkinson's patients are simultaneously guided in adjusting their dopaminergic medications, which can often be reduced substantially after DBS activation. Programming continues at monthly intervals for three to six months, then every six to twelve months as parameters stabilise. Patients and carers are trained to use a patient controller to turn the device on and off, and modern rechargeable IPGs require external charging for one to two hours per week. Device-specific precautions include avoiding strong electromagnetic fields (large industrial magnets, MRI without specific DBS-approved protocols), and carrying a device identification card at all times for emergency situations. Annual battery level checks and device interrogation are performed in the DBS clinic. The treating neurology team coordinates with other specialists for any surgical or imaging procedures to manage the implanted device safely.